CHICAGO—ACR leaders described a series of looming legislative and regulatory threats to rheumatologists and their patients—including the proposed collapsing of evaluation and management (E/M) coding and potential changes to step therapy rules—and urged everyone in the field to make their voices heard to quash the proposals.
They also recounted recent victories in the policy realm by the ACR—among them, changes to reimbursement for biosimilars and the easing of cuts to imaging reimbursement—which they say show that stepping into an advocacy role can bring results that matter.
The call to action came in a session here at the 2018 ACR/ARHP Annual Meeting.
The changes to the E/M codes are ostensibly meant to simplify documentation, by blending E/M levels 2 through 5 into a single payment, requiring documentation only at level 2, which is less onerous. But the ACR and other medical organizations say it will lower reimbursement for more complex cases.